

Test Report

Patient Information

| | | | |
|----------|-----|---------------|-----------------------|
| Name | Sex | Date of Birth | Medical Record Number |
| Jane Lee | F | 01/01/1960 | 00998877 |

kidneyintelX.dkd LEVEL



Moderate

In the clinical performance study*, approximately 17% (95% CI 12% to 22%) of patients with Moderate kidneyintelX.dkd Levels experienced progressive decline in kidney function decline within 5 years after their test result.

Signed
Michael Smith PhD, MD.

Report Date Time
03/14/2023 10:05 AM (UTC)

Laboratory Director: CLIA Number: Renalytix, 101 6th Avenue, 3rd Floor,
Michael Smith PhD, MD. 112233445566 Room 324, New York, NY 10013

| kidneyintelX.dkd Level | Percent of Patients Experiencing Progressive Decline in Kidney Function (95% CI) | Percent of Patients Experiencing End Stage Kidney Disease (95% CI) |
|------------------------|--|--|
| Low | 4.6% (2.7% – 7.2%) | 0.0% |
| Moderate | 16.7% (12.1% – 22.2%) | 3.1% (1.2% – 6.2%) |
| High | 41.8% (28.7% – 55.9%) | 18.2% (9.1% – 30.9%) |

*Based on clinical performance study results in the kidneyintelX.dkd Product Technical Sheet. The kidneyintelX.dkd Levels (Low, Moderate, and High) correlate with the probability of progressive decline in kidney function.

To receive a kidneyintelX.dkd Product Technical Sheet, contact Client Services at (888) 203-2725 or at clientservices@renalytix.com.

kidneyintelX.com  renalytix™

kidneyintelX.dkd Product Technical Sheet (printed copy) is promptly provided at no cost upon request.